206 related articles for article (PubMed ID: 35970682)
1. [Bladder-sparing trimodal therapy for muscle invasive bladder cancer].
Khalifa J; Roumiguié M; Pouessel D; Sargos P
Cancer Radiother; 2022 Oct; 26(6-7):771-778. PubMed ID: 35970682
[TBL] [Abstract][Full Text] [Related]
2. Bladder sparing surgery in high-grade bladder cancer.
Yakovlev PG; Klyushin DA; Vereshchako RI
Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
[TBL] [Abstract][Full Text] [Related]
3. Is trimodal therapy the current standard for muscle-invasive bladder cancer?
López Valcárcel M; Barrado Los Arcos M; Ferri Molina M; Cienfuegos Belmonte I; Duque Santana V; Gajate Borau P; Fernández Ibiza J; Álvarez Maestro M; Sargos P; López Campos F; Couñago F
Actas Urol Esp (Engl Ed); 2024 Jun; 48(5):345-355. PubMed ID: 38575067
[TBL] [Abstract][Full Text] [Related]
4. Trimodal therapy for muscle-invasive bladder cancer.
Mathes J; Rausch S; Todenhöfer T; Stenzl A
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1219-1229. PubMed ID: 30324833
[TBL] [Abstract][Full Text] [Related]
5. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
6. Can bladder preservation therapy come to the center stage?
Inamoto T; Ibuki N; Komura K; Juri H; Yamamoto K; Yamamoto K; Fujita K; Nonomura N; Narumi Y; Azuma H
Int J Urol; 2018 Feb; 25(2):134-140. PubMed ID: 29171098
[TBL] [Abstract][Full Text] [Related]
7. Trimodal therapy in muscle invasive bladder cancer management.
Polo-Alonso E; Kuk C; Guruli G; Paul AK; Thalmann G; Kamat A; Solsona E; Thalmann G; Urdaneta AI; Zlotta AR; Mir MC
Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
[TBL] [Abstract][Full Text] [Related]
8. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.
El-Achkar A; Souhami L; Kassouf W
Curr Urol Rep; 2018 Nov; 19(12):108. PubMed ID: 30392150
[TBL] [Abstract][Full Text] [Related]
9. [Organ preservation by chemoradiation for bladder cancer].
Durdux C; Fabiano E; Méjean A
Cancer Radiother; 2019 Oct; 23(6-7):732-736. PubMed ID: 31400955
[TBL] [Abstract][Full Text] [Related]
10. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
11. Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future.
Koga F
Expert Rev Anticancer Ther; 2023; 23(11):1127-1139. PubMed ID: 37753554
[TBL] [Abstract][Full Text] [Related]
12. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer.
Feldman AS; Kulkarni GS; Bivalacqua TJ; Black PC; Delacroix S; Lerner SP; Kamat AM; Kassouf W
Urol Oncol; 2022 Oct; 40(10):442-450. PubMed ID: 33642229
[TBL] [Abstract][Full Text] [Related]
13. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
Jiang DM; Chung P; Kulkarni GS; Sridhar SS
Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
[TBL] [Abstract][Full Text] [Related]
14. Bladder-sparing treatment options in localized muscle-invasive bladder cancer.
Nason GJ; Ajib K; Tan GH; Kulkarni GS
Expert Rev Anticancer Ther; 2020 Mar; 20(3):179-188. PubMed ID: 32129122
[No Abstract] [Full Text] [Related]
15. Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule.
Alati A; Fabiano E; Geiss R; Mareau A; Charles-Nelson A; Bibault JE; Giraud P; Kreps S; Méjean A; Housset M; Durdux C
J Geriatr Oncol; 2022 Sep; 13(7):978-986. PubMed ID: 35717533
[TBL] [Abstract][Full Text] [Related]
16. Organ-sparing procedures in GU cancer: part 3-organ-sparing procedures in urothelial cancer of upper tract, bladder and urethra.
Khalil MI; Alliston JT; Bauer-Erickson JJ; Davis R; Bissada NK; Kamel MH
Int Urol Nephrol; 2019 Nov; 51(11):1903-1911. PubMed ID: 31352580
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?
Kuczyk M; Turkeri L; Hammerer P; Ravery V;
Eur Urol; 2003 Jul; 44(1):57-64. PubMed ID: 12814676
[TBL] [Abstract][Full Text] [Related]
18. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
[TBL] [Abstract][Full Text] [Related]
19. Cost of Bladder Cancer Care: A Single-center Comparison of Radical Cystectomy and Trimodal Therapy.
Magee DE; Cheung DC; Hird AE; Chung P; Warde P; Catton C; Berlin A; Zlotta A; Fleshner NE; Kulkarni GS
Urol Pract; 2023 Jul; 10(4):293-299. PubMed ID: 37103562
[TBL] [Abstract][Full Text] [Related]
20. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?
Mathieu R; Lucca I; Klatte T; Babjuk M; Shariat SF
Curr Opin Urol; 2015 Sep; 25(5):476-82. PubMed ID: 26125510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
